Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut?

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks on our list.

TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. The updated target was included in the firm’s second-quarter outlook for the MedTech, Life Sciences Tools, and Diagnostics industries. Evercore ISI noted that sector conditions remain supported by relatively healthy procedure volumes and capital spending trends, according to a research note shared with investors.

Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut?

Earlier on July 1, Tandem Diabetes Care announced that its t: slim X2 insulin pump featuring Control-IQ+ automated insulin delivery technology is now compatible with Abbott Laboratories (NYSE:ABT)’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor across five countries. The expansion provides users in the United Kingdom, Switzerland, Sweden, Finland, and Italy with additional CGM options while using Tandem’s automated insulin delivery system. The company expects to broaden availability to more European markets, including Belgium, the Netherlands, and Germany, during 2026. Tandem stated that expanding sensor compatibility supports greater flexibility for people using automated insulin delivery technology and enhances choice within its diabetes management ecosystem.

Abbott Laboratories (NYSE:ABT) is a global healthcare innovator advancing medical devices, diagnostics, nutrition, and pharmaceuticals. Its key innovations include FreeStyle Libre continuous glucose monitoring, AVEIR leadless pacemakers, and digital health technologies, while expanding access to advanced healthcare solutions worldwide.

While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1